Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced its results for the fourth quarter and full year ended December 31, 2010, Completed enrollment in a 220-patient Phase 2 trial for patients experiencing their first heart attack. Submitted Prochymal New Drug Submission (NDS) to the Biologics and Genetic Therapies Directorate of Health Canada Received Orphan Drug designation from Swissmedic, the Swiss Agency for Therapeutic Products, and the Therapeutic Goods Administration, Australia’s regulatory agency for medical drugs and devices, for Prochymal as a treatment for GvHD, making the drug eligible for expedited review. Granted Priority Review for Prochymal by Health Canada.

Osiris Therapeutics, Inc., a stem cell therapeutic company, focuses on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States and internationally.

****

Proper Power and Energy, Inc. (PPWE.PK)

Previously, Proper Power and Energy, Inc. has restructured its executive management team and entered into a strategic alliance.

Andrew J. Kacic replaced Joseph Abdo as President of Proper Power & Energy. Mr. Kacic brings more than 32 years of progressive experience as a chief executive in oil and gas, investment banking, insurance services and public securities.

Concurrently to the management restructuring, the Company has entered into a strategic alliance with Douglas Kiggins, founder of Mayo Energy Partners. Mr. Kiggins will assist Mr. Kacic in the development of the Company’s Utah asset, with the target goal of drilling the first exploratory well in Utah by third Quarter 2011. ( Read More http://crweselect.com/21837/stock-alerts/osir-ppwepk-ultr-orfgpk-jaso-cr... )